Literature DB >> 36267779

Sacituzumab govitecan and other antibody-drug conjugates targeting trophoblast cell-surface antigen 2 (Trop-2) in breast cancer.

Ashley Matusz-Fisher1, Antoinette R Tan1.   

Abstract

Entities:  

Year:  2022        PMID: 36267779      PMCID: PMC9577799          DOI: 10.21037/atm-22-1892

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


× No keyword cloud information.
  24 in total

Review 1.  Triple-negative breast cancer.

Authors:  William D Foulkes; Ian E Smith; Jorge S Reis-Filho
Journal:  N Engl J Med       Date:  2010-11-11       Impact factor: 91.245

2.  Upregulation of Trop-2 quantitatively stimulates human cancer growth.

Authors:  M Trerotola; P Cantanelli; E Guerra; R Tripaldi; A L Aloisi; V Bonasera; R Lattanzio; R de Lange; U H Weidle; M Piantelli; S Alberti
Journal:  Oncogene       Date:  2012-02-20       Impact factor: 9.867

3.  Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer.

Authors:  Xiaoxian Li; Jing Yang; Limin Peng; Aysegul A Sahin; Lei Huo; Kevin C Ward; Ruth O'Regan; Mylin A Torres; Jane L Meisel
Journal:  Breast Cancer Res Treat       Date:  2016-11-25       Impact factor: 4.872

4.  Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.

Authors:  Peter Schmid; Javier Cortes; Rebecca Dent; Lajos Pusztai; Heather McArthur; Sherko Kümmel; Jonas Bergh; Carsten Denkert; Yeon Hee Park; Rina Hui; Nadia Harbeck; Masato Takahashi; Michael Untch; Peter A Fasching; Fatima Cardoso; Jay Andersen; Debra Patt; Michael Danso; Marta Ferreira; Marie-Ange Mouret-Reynier; Seock-Ah Im; Jin-Hee Ahn; Maria Gion; Sally Baron-Hay; Jean-François Boileau; Yu Ding; Konstantinos Tryfonidis; Gursel Aktan; Vassiliki Karantza; Joyce O'Shaughnessy
Journal:  N Engl J Med       Date:  2022-02-10       Impact factor: 91.245

5.  Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis.

Authors:  Lisa A Carey; Delphine Loirat; Kevin Punie; Aditya Bardia; Véronique Diéras; Florence Dalenc; Jennifer R Diamond; Christel Fontaine; Grace Wang; Hope S Rugo; Sara A Hurvitz; Kevin Kalinsky; Joyce O'Shaughnessy; Sibylle Loibl; Luca Gianni; Martine Piccart; Yanni Zhu; Rosemary Delaney; See Phan; Javier Cortés
Journal:  NPJ Breast Cancer       Date:  2022-06-09

6.  Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline.

Authors:  Larissa A Korde; Mark R Somerfield; Lisa A Carey; Jennie R Crews; Neelima Denduluri; E Shelley Hwang; Seema A Khan; Sibylle Loibl; Elizabeth A Morris; Alejandra Perez; Meredith M Regan; Patricia A Spears; Preeti K Sudheendra; W Fraser Symmans; Rachel L Yung; Brittany E Harvey; Dawn L Hershman
Journal:  J Clin Oncol       Date:  2021-01-28       Impact factor: 44.544

7.  Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.

Authors:  Javier Cortés; Sung-Bae Kim; Wei-Pang Chung; Seock-Ah Im; Yeon Hee Park; Roberto Hegg; Min Hwan Kim; Ling-Ming Tseng; Vanessa Petry; Chi-Feng Chung; Hiroji Iwata; Erika Hamilton; Giuseppe Curigliano; Binghe Xu; Chiun-Sheng Huang; Jee Hyun Kim; Joanne W Y Chiu; Jose Luiz Pedrini; Caleb Lee; Yali Liu; Jillian Cathcart; Emarjola Bako; Sunil Verma; Sara A Hurvitz
Journal:  N Engl J Med       Date:  2022-03-24       Impact factor: 176.079

Review 8.  The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target.

Authors:  David M Goldenberg; Rhona Stein; Robert M Sharkey
Journal:  Oncotarget       Date:  2018-06-22

9.  Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.

Authors:  A Bardia; S M Tolaney; K Punie; D Loirat; M Oliveira; K Kalinsky; A Zelnak; P Aftimos; F Dalenc; S Sardesai; E Hamilton; P Sharma; S Recalde; E C Gil; T Traina; J O'Shaughnessy; J Cortes; M Tsai; L Vahdat; V Diéras; L A Carey; H S Rugo; D M Goldenberg; Q Hong; M Olivo; L M Itri; S A Hurvitz
Journal:  Ann Oncol       Date:  2021-06-08       Impact factor: 32.976

10.  Trop-2 is a determinant of breast cancer survival.

Authors:  Federico Ambrogi; Marco Fornili; Patrizia Boracchi; Marco Trerotola; Valeria Relli; Pasquale Simeone; Rossana La Sorda; Rossano Lattanzio; Patrizia Querzoli; Massimo Pedriali; Mauro Piantelli; Elia Biganzoli; Saverio Alberti
Journal:  PLoS One       Date:  2014-05-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.